BioPharma Clinical Trials
Biocytogen and CtM Bio Advance in Developing Multi-Specific T Cell Engager against WT1/HLA-A02
In just one year since the start of the collaboration, the companies have identified a WT1/HLA-A02-specific T cell engager (WT1xCD3x4-1BB tri-specific anti...
December 28, 2023 | News
Nectin Therapeutics Expands Clinical Trial to Israel, Progresses Swiftly
Nectin Therapeutics Ltd., (Nectin), a biotechnology company developing novel targeted immunotherapies that address resistance to approved immune oncology t...
December 27, 2023 | News
Jemincare Announces 6 Approvals of Clinical Trials for its Innovative Drugs
On December 20, NMPA has approved a clinical trial for JMKX003801 to treat serious infection caused by Gram-negative bacteria. Drug resistance of anti...
December 27, 2023 | News
Asieris' APL-2301 Approved for Phase I Trials in Australia for Acinetobacter baumannii Infection
The planned clinical trial in Australia will be the first-in-human Phase I trial for APL-2301. It aims to evaluate the safety, tolerability, phar...
December 26, 2023 | News
Oncoshot Collaborates with Zhejiang Ablaze for Data-Driven Drug Development in China
This collaboration brings together complementary strengths - Oncoshot's capabilities in data analysis and insights generation with Ablaze's recent expansio...
December 26, 2023 | News
TransThera Completes First Patient Dosing in US for Global Phase 3 Trial of Tinengotinib in FGFRi Relapsed/Refractory Cholangiocarcinoma
This study is a Phase 3, randomized, controlled, global multicenter study to evaluate the efficacy and safety of oral tinengotinib versus physician's choic...
December 22, 2023 | News
Everest Medicines' Partner Calliditas Announces Nefecon® as Sole FDA-Approved Treatment for Slowing IgA Nephropathy Kidney Decline
The FDA approval is for adults with primary IgAN who are at risk for disease progression, irrespective of proteinuria levels. Nefecon® is now a...
December 21, 2023 | News
BioCity Doses First Patient in Phase Ib/II Trial of BC3402 Anti-TIM-3 mAb with IMFINZI for Advanced Hepatocellular Carcinoma
The study is being conducted at Zhongshan Hospital with Prof. Jia Fan as the principal investigator. Dr. Fan is a world-renowned liver cancer sur...
December 21, 2023 | News
NMPA Accepts Mabwell's 8MW0511 Injection New Drug Application
8MW0511, a Class 1 therapeutic biological product, is a new generation of long-acting G-CSF (modified cytokine with high activity) with independent intelle...
December 20, 2023 | News
Australian Neuren Phase 2 Trial Reveals Significant Improvements in Phelan-McDermid Syndrome
Highlights: Significant improvement was assessed by both clinicians and caregivers across multiple efficacy measures Improvements were con...
December 19, 2023 | News
Advancing Lung Cancer Treatment: Insights from Professor Benjamin Solomon on the ALINA Study and the Future of ALK-Positive NSCLC
In an exclusive BioPharma APAC interview, Professor Benjamin Solomon, a distinguished Medical Oncologist at the Peter MacCallum Cancer Centre, Australia, a...
December 18, 2023 | News
InnoCare's TYK2 Inhibitor ICP-332 Meets Phase II Endpoint in Atomic Dermatitis Study
ICP-332 in AD patients treated for 4 weeks demonstrated excellent efficacy and safety profile. ICP-332 achieved multiple efficacy endpoints including Eczem...
December 18, 2023 | News
GC Biopharma's ALYGLO™ 10% Liquid FDA Approved for Adult Primary Immunodeficiency.
The ALYGLO pivotal phase 3 clinical study followed FDA guidance for the treatment of patients with PI. The clinical trial (NCT02783482) GC5107B was a prosp...
December 18, 2023 | News
Fosun Pharma's Antimalarial Drug Trial Gets 500 Million Yen Boost from GHIT Fund for Global Accessibility Initiative
The Japan-based Global Health Innovative Technology Fund (GHIT Fund) announced that it will invest approximately US$3.3 million (approximate...
December 15, 2023 | News
Most Read
- Lack of Regular Screening Fuels Rise in Late-Stage Breast Cancer in Hong Kong, New Report Reveals
- BIOCHINA 2025: Connecting Global Innovators with China's Leading Biotech Firms
- Leon Wyszkowski, President of Analytical Services, Discusses Thermo Fisher's Strategic Move: Expanding Bioanalytical Capabilities in Europe with New Sweden Lab
- The Role of Policy and Public Health Initiatives in Addressing Women's Cancer Care in Asia
- Redefining Patient Safety in the Age of Healthtech
Bio Jobs
- Avance Clinical Appoints Jessica Han as Director of Asian Operations, Strengthening Commitment to the Asian Market
- Bristol Myers Squibb Employees Cycle Coast-to-Coast to Raise $1 Million for Cancer Research
- Pfizer Australia Commits $150M to Upgrade Melbourne Facility, Bolstering Global Fight Against Antimicrobial Resistance
- SMi Systems Appoints Dr. Stefan Hamill as Vice President of Strategy to Drive Commercialisation and Growth
- Thermo Fisher Scientific Appoints William Hung as Senior Director and General Manager for Taiwan
- Cytiva Appoints Industry Veteran Pierre-Alain Ruffieux as Chief Operating Officer
News
Editor Picks
